Guided Therapeutics (GTHP) EBIT (2010 - 2025)
Guided Therapeutics (GTHP) reported EBIT of -$710000.0 for Q4 2025, down 32.96% on a YoY basis from -$1.1 million in Q4 2024, and down 46.39% sequentially from -$485000.0 in Q3 2025.
Guided Therapeutics (GTHP) EBIT (2010 - 2025) Analysis & Trends
Guided Therapeutics (GTHP) has 16 years of EBIT data on file, last reported at -$710000.0 in Q4 2025.
- For the quarter ending Q4 2025, EBIT fell 32.96% year-over-year to -$710000.0; the trailing twelve-month figure through Dec 2025 stood at -$2.4 million (down 12.47% YoY), and the FY2025 full-year result was -$2.4 million, down 12.52% from the prior year.
- EBIT fell to -$710000.0 in Q4 2025, from -$485000.0 in the prior quarter.
- In the past five years, EBIT ranged from a high of -$359000.0 in Q1 2024 to a low of -$1.5 million in Q2 2023.
- A 5-year average of -$678750.0 and a median of -$592000.0 in 2021 frame the typical range for EBIT.
- Across the five-year window, EBIT sank 240.08% in 2021 and jumped 57.41% in 2024, its largest moves.
- Tracing GTHP's EBIT over 5 years: stood at -$435000.0 in 2021, then sank by 117.93% to -$948000.0 in 2022, then surged by 48.84% to -$485000.0 in 2023, then dropped by 10.1% to -$534000.0 in 2024, then slumped by 32.96% to -$710000.0 in 2025.
- Business Quant data shows GTHP's EBIT at -$710000.0 in Q4 2025, -$485000.0 in Q3 2025, and -$763000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 1.35 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 936.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 1.87 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 1.10 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 477.60 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 255.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 282.15 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 515.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Guided Therapeutics | 21.96 Mn | 21.89 Mn | 458,000.00 | -710,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -710,000.00 |
| Sep 30, 2025 | -485,000.00 |
| Jun 30, 2025 | -763,000.00 |
| Mar 31, 2025 | -414,000.00 |
| Dec 31, 2024 | -534,000.00 |
| Sep 30, 2024 | -561,000.00 |
| Jun 30, 2024 | -655,000.00 |
| Mar 31, 2024 | -359,000.00 |
| Dec 31, 2023 | -485,000.00 |
| Sep 30, 2023 | -623,000.00 |
| Jun 30, 2023 | -1.51 Mn |
| Mar 31, 2023 | -843,000.00 |
| Dec 31, 2022 | -948,000.00 |
| Sep 30, 2022 | -1.22 Mn |
| Jun 30, 2022 | -717,000.00 |
| Mar 31, 2022 | -443,000.00 |
| Dec 31, 2021 | -435,000.00 |
| Sep 30, 2021 | -487,000.00 |
| Jun 30, 2021 | -561,000.00 |
| Mar 31, 2021 | -823,000.00 |